| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442551 | European Journal of Cancer | 2015 | 7 Pages |
Abstract
Duration of first-line targeted treatment for mRCC was significantly shorter for patients with RI, and may have translated into a trend to shorter PFS. These results highlight the need for optimal management of side-effects in patients with mRCC and RI.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Radek Lakomy, Marek Svoboda, Igor Kiss, Milada Zemanova, Ondrej Fiala, Katerina Kubackova, Oldrich Coufal, Tomas Pavlik, Ladislav Dusek, Rostislav Vyzula, Tomas Buchler,